JP2008529486A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008529486A5 JP2008529486A5 JP2007553650A JP2007553650A JP2008529486A5 JP 2008529486 A5 JP2008529486 A5 JP 2008529486A5 JP 2007553650 A JP2007553650 A JP 2007553650A JP 2007553650 A JP2007553650 A JP 2007553650A JP 2008529486 A5 JP2008529486 A5 JP 2008529486A5
- Authority
- JP
- Japan
- Prior art keywords
- hla
- peptide
- molecule
- fragment
- epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 30
- 239000012634 fragment Substances 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 claims 7
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 7
- 102100038823 RNA-binding protein 45 Human genes 0.000 claims 7
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims 5
- 108010028921 Lipopeptides Proteins 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 230000003902 lesion Effects 0.000 claims 5
- 230000001613 neoplastic effect Effects 0.000 claims 5
- 101150059079 EBNA1 gene Proteins 0.000 claims 4
- 102100040482 HLA class II histocompatibility antigen, DR beta 3 chain Human genes 0.000 claims 4
- 102100028640 HLA class II histocompatibility antigen, DR beta 5 chain Human genes 0.000 claims 4
- 108010093013 HLA-DR1 Antigen Proteins 0.000 claims 4
- 108700037339 HLA-DR13 antigen Proteins 0.000 claims 4
- 108010063970 HLA-DR15 antigen Proteins 0.000 claims 4
- 108010064885 HLA-DR3 Antigen Proteins 0.000 claims 4
- 108010046732 HLA-DR4 Antigen Proteins 0.000 claims 4
- 108010001041 HLA-DR7 Antigen Proteins 0.000 claims 4
- 108010061311 HLA-DRB3 Chains Proteins 0.000 claims 4
- 108010016996 HLA-DRB5 Chains Proteins 0.000 claims 4
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 claims 4
- 101150113776 LMP1 gene Proteins 0.000 claims 4
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 102000037865 fusion proteins Human genes 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102100028636 HLA class II histocompatibility antigen, DR beta 4 chain Human genes 0.000 claims 3
- 108010059234 HLA-DPw4 antigen Proteins 0.000 claims 3
- -1 HLA-DR11 Proteins 0.000 claims 3
- 108010040960 HLA-DRB4 Chains Proteins 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000003153 chemical reaction reagent Substances 0.000 claims 3
- 230000002163 immunogen Effects 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 230000027455 binding Effects 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 1
- 101100532584 Clostridium perfringens (strain 13 / Type A) sspC1 gene Proteins 0.000 claims 1
- 101150034979 DRB3 gene Proteins 0.000 claims 1
- 101150082328 DRB5 gene Proteins 0.000 claims 1
- 101100095550 Homo sapiens SENP7 gene Proteins 0.000 claims 1
- 108700020134 Human immunodeficiency virus 1 nef Proteins 0.000 claims 1
- 101100278514 Oryza sativa subsp. japonica DRB2 gene Proteins 0.000 claims 1
- 101100117569 Oryza sativa subsp. japonica DRB6 gene Proteins 0.000 claims 1
- 101100119347 Plasmodium falciparum EXP-1 gene Proteins 0.000 claims 1
- 101150098865 SSP2 gene Proteins 0.000 claims 1
- 102100031406 Sentrin-specific protease 7 Human genes 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0501198 | 2005-02-07 | ||
| FR0501198A FR2881746B1 (fr) | 2005-02-07 | 2005-02-07 | Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications |
| PCT/FR2006/000229 WO2006082313A2 (fr) | 2005-02-07 | 2006-02-02 | Epitopes t cd4+ des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus db la population caucasienne et leurs applications |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008529486A JP2008529486A (ja) | 2008-08-07 |
| JP2008529486A5 true JP2008529486A5 (enExample) | 2009-02-26 |
| JP4972562B2 JP4972562B2 (ja) | 2012-07-11 |
Family
ID=35116028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007553650A Expired - Fee Related JP4972562B2 (ja) | 2005-02-07 | 2006-02-02 | 白人個体群の個体の大多数により認識され得るエプスタイン−バーウイルスのｉ型及びｉｉ型潜伏期抗原のｔｃｄ４＋エピトープ、及びその適用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20090130134A1 (enExample) |
| EP (1) | EP1861418B1 (enExample) |
| JP (1) | JP4972562B2 (enExample) |
| AT (1) | ATE455791T1 (enExample) |
| CA (1) | CA2596929C (enExample) |
| DE (1) | DE602006011859D1 (enExample) |
| FR (1) | FR2881746B1 (enExample) |
| WO (1) | WO2006082313A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU696167B2 (en) * | 1993-10-29 | 1998-09-03 | Trustees Of Boston University | Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents |
| CA2324426A1 (en) * | 1998-02-11 | 1999-08-19 | Douglas V. Faller | Compositions and methods for the treatment of cystic fibrosis |
| FR2830940B1 (fr) | 2001-10-17 | 2007-06-15 | Commissariat Energie Atomique | Procede de selection de ligands d'hla-dp4 et ses applications |
| GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
| ES2402956T3 (es) | 2007-08-15 | 2013-05-10 | Circassia Limited | Péptido con formación de dímeros reducida |
| WO2010105112A1 (en) * | 2009-03-11 | 2010-09-16 | Hemaquest Pharmaceuticals, Inc. | Detection of short-chain fatty acids in biological samples |
| US20110086869A1 (en) | 2009-09-24 | 2011-04-14 | The Trustees Of Boston University | Methods for treating viral disorders |
| CN102802412A (zh) | 2009-12-08 | 2012-11-28 | 海玛奎斯特医药公司 | 用于治疗红细胞病症的方法及低剂量方案 |
| WO2011113013A2 (en) | 2010-03-11 | 2011-09-15 | Hemaquest Pharmaceuticals, Inc. | Methods and compositions for treating viral or virally-induced conditions |
| ES2607148T3 (es) | 2012-05-08 | 2017-03-29 | The Johns Hopkins University | Métodos y composiciones para infusión de poblaciones seleccionadas de linfocitos alogénicos con prendimiento transitorio para tratar cáncer |
| CA2953747A1 (en) | 2013-06-28 | 2014-12-31 | Auckland Uniservices Limited | Amino acid and peptide conjugates and conjugation process |
| JP2018505152A (ja) * | 2014-12-23 | 2018-02-22 | アン ブリンブル マーガレット | アミノ酸複合体及びペプチド複合体ならびにそれらの使用 |
| WO2017145097A2 (en) | 2016-02-26 | 2017-08-31 | Auckland Uniservices Limited | Amino acid and peptide conjugates and conjugation process |
| JP7373991B2 (ja) | 2016-07-15 | 2023-11-06 | ビラクタ セラピューティクス，インク． | 免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤 |
| KR102565256B1 (ko) | 2017-02-12 | 2023-08-08 | 바이오엔테크 유에스 인크. | Hla 기반 방법 및 조성물, 및 이들의 용도 |
| BR112020012361A2 (pt) * | 2017-12-20 | 2020-11-24 | Glaxosmithkline Biologicals S.A. | constructos de antígeno do vírus epstein-barr |
| MX2021007556A (es) * | 2018-12-21 | 2021-09-10 | Biontech Us Inc | Método y sistemas de predicción de epítopos específicos de hla de clase ii y caracterización de células t cd4+. |
| KR20220034736A (ko) | 2019-05-31 | 2022-03-18 | 비락타 서브시디어리 인크. | 히스톤 데아세틸라제 억제제를 사용하여 바이러스 관련 암을 치료하는 방법 |
| MX2022009255A (es) * | 2020-02-10 | 2023-02-23 | Univ Johns Hopkins | Inmunoterapia contra cáncer usando transfusiones de celulas t alogenicas cd4+ específicas de tumor. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040157780A1 (en) * | 1993-11-29 | 2004-08-12 | Epimmune Inc. | CTL inducing peptides from c-erb2 (HER-2/neu) |
| WO1996002563A1 (en) * | 1994-07-13 | 1996-02-01 | Cornell Research Foundation, Inc. | Epstein-barr virus nuclear antigen 1 protein and its expression and recovery |
| US20020141995A1 (en) * | 1997-06-10 | 2002-10-03 | Irvin Charles G. | Method for treatment of inflammatory disease |
| WO2001037868A1 (en) * | 1999-11-24 | 2001-05-31 | Oklahoma Medical Research Foundation | Assays and therapies for latent viral infection |
| EP1229043A1 (en) * | 2001-01-30 | 2002-08-07 | Cyto-Barr B.V. | Peptides derived from Epstein Barr virus (EBV) proteins LMP1, LMP2 and BARF1 antibody reagents reactive therewith |
| GB0214528D0 (en) * | 2002-06-24 | 2002-08-07 | Univ Aberdeen | Materials and methods for induction of immune tolerance |
| WO2004007536A2 (en) * | 2002-07-16 | 2004-01-22 | Affinium Pharmaceuticals, Inc. | Interactions of the epstein-barr virus protein ebna1, and uses thereof |
| WO2004041849A1 (en) * | 2002-11-07 | 2004-05-21 | The Council Of The Queensland Institute Of Medical Research | Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor |
| US20040141995A1 (en) * | 2002-12-10 | 2004-07-22 | Rongfu Wang | MHC class I-restricted and MHC class II-restricted EBNA1 peptides |
-
2005
- 2005-02-07 FR FR0501198A patent/FR2881746B1/fr not_active Expired - Fee Related
-
2006
- 2006-02-02 AT AT06709221T patent/ATE455791T1/de not_active IP Right Cessation
- 2006-02-02 DE DE602006011859T patent/DE602006011859D1/de active Active
- 2006-02-02 JP JP2007553650A patent/JP4972562B2/ja not_active Expired - Fee Related
- 2006-02-02 CA CA2596929A patent/CA2596929C/fr not_active Expired - Fee Related
- 2006-02-02 EP EP06709221A patent/EP1861418B1/fr not_active Not-in-force
- 2006-02-02 US US11/883,814 patent/US20090130134A1/en not_active Abandoned
- 2006-02-02 WO PCT/FR2006/000229 patent/WO2006082313A2/fr not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008529486A5 (enExample) | ||
| Celis et al. | Recognition of hepatitis B surface antigen by human T lymphocytes. Proliferative and cytotoxic responses to a major antigenic determinant defined by synthetic peptides. | |
| TWI232108B (en) | Synthetic peptide vaccines for foot-and-mouth disease | |
| US4708871A (en) | Antigenically active amino acid sequences | |
| CA1194794A (en) | Synthetic peptide specific antigenic determinant and method of manufacturing antigenic materials therefrom | |
| Tugyi et al. | The effect of cyclization on the enzymatic degradation of herpes simplex virus glycoprotein D derived epitope peptide | |
| JP2003529319A (ja) | ＨＩＶ−１ｇｐ４１を標的化する広範に中和する抗体を誘発する方法 | |
| NZ703560A (en) | Method for activating helper t cell | |
| JP2005505503A5 (enExample) | ||
| JPS59500498A (ja) | １ａ型乳頭腫ウイルスゲノムのＬ１及びＬ２領域由来のＤＮＡ断片 | |
| RU2013109273A (ru) | Полипептиды, используемые для лечения и/или подавления инфекций, вызываемых вирусом гриппа | |
| US4761470A (en) | Immunogenic synthetic peptide capable of eliciting herpes simplex virus neutralizing antibody | |
| Nestorowicz et al. | Antibodies elicited by influenza virus hemagglutinin fail to bind to synthetic peptides representing putative antigenic sites | |
| Askelöf et al. | Protective immunogenicity of two synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1. | |
| AU2011340430A1 (en) | Immune restricted peptides with increased efficacy | |
| Burt et al. | Diversity of the class II (I-Ak/I-Ek)-restricted T cell repertoire for influenza hemagglutinin and antigenic drift. Six nonoverlapping epitopes on the HA1 subunit are defined by synthetic peptides. | |
| CA2909669C (en) | Antiviral activity of gas6 inhibitor | |
| WO2003012107A1 (en) | Hepatitis b virus pre-s1 derived synthetic polypeptides and uses thereof | |
| Parra-Lopez et al. | Major histocompatibility complex and T cell interactions of a universal T cell epitope from Plasmodium falciparum circumsporozoite protein | |
| JPH06321808A (ja) | Ｈｉｖ主要中和決定基の新規な実施態様 | |
| GB2128621A (en) | Polypeptides useful in vaccination against enteroviruses | |
| CA2139517A1 (en) | Immunological conjugates of ompc and hiv-specific selected principal neutralization epitopes | |
| CN102775478B (zh) | 口蹄疫病毒抗原多肽及疫苗 | |
| Maryanski et al. | The diversity of antigen-specific TCR repertoires reflects the relative complexity of epitopes recognized | |
| AU662534B2 (en) | Peptides for use in induction of T cell activation against HIV-1 |